Researcher Database
Prof. Dr. Katharina Götze
Ismaninger Str. 22
81675 München
Program
Exploitation of Oncogenic Mechanisms (EOM)
Summary
Katharina Götze is deputy clinical director at the Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie des Klinikums rechts der Isar.
Her research group on Hematopoeitic Stem Cells and Microenvironment is focused on studying leukemic stem cells in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In particular, they are interested in the interaction between leukemic stem cells and their microenvironment (niche) in the bone marrow to identify and target critical pathways directing clonal evolution and enabling survival of leukemic stem cells through interaction with the stem cell niche.
Current projects have an emphasis on epigenetic changes in the bone marrow microenvironment during clonal evolution in MDS and AML and involve use of transgenic and transplantation mouse models as well as primary human bone marrow samples.
Further information is provided at:
https://med3.mri.tum.de/de/hematopoeitic-stem-cells-and-microenvironment
DKTK Junior Group Leader for Cancer Systems Biology
Single-cell approaches have not only revealed a wide variety of cell states, characterized by cells exhibiting striking differences in their transcriptional profile, but have also illuminated the mechanisms underlying state transitions in health and disease. Cellular plasticity and adaptive state changes have recently emerged as a basis for therapeutic resistance in cancer, and a better understanding of how cell state transitions are regulated is critical to develop therapeutic approaches that can overcome therapy resistance.
Our research focuses on understanding the mechanisms driving non-genetic cellular heterogeneity and therapy resistance in malignancy. Using novel single-cell sequencing approaches, we seek to develop new experimental and computational strategies to define altered cell states in both, cancer and immune cells. Our aim is to leverage a data driven strategy combined with single cell genomics and systems biology to address the challenges posed by heterogeneity in cancer, and to develop new strategies to overcome it, with the aim of translating laboratory-based findings into the clinic.